Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population

Zena and Michael Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA.
Journal of Thrombosis and Haemostasis (Impact Factor: 5.55). 05/2010; 8(5):1018-26. DOI: 10.1111/j.1538-7836.2010.03792.x
Source: PubMed

ABSTRACT Gene-based warfarin dosing algorithms have largely been developed in homogeneous populations, and their generalizability has not been established.
We sought to assess the performance of published algorithms in a racially diverse and multiethnic sample, and determine if additional clinical variables or genetic variants associated with dose could enhance algorithm performance.
In 145 compliant patients on warfarin with a goal international normalized ratio (INR) of 2-3, stable, therapeutic doses were compared with predicted doses using 12 reported algorithms that incorporated CYP2C9 and VKORC1 variants. Additional covariates tested with each model included race, concurrent medications, medications known to interact with warfarin and previously described CYP4F2, CALU and GGCX variants.
The mean patient age was 67 +/- 14 years; 90 (62%) were male. Eighty-two (57%) were Caucasian, 28 (19%) African-American, 20 (14%) Hispanic and 15 (10%) Asian. The median warfarin dose was 35 mg per week (interquartile range 23-53 mg per week). Gene-based dosing algorithms explained 37-55% of the variation in warfarin dose requirements. Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.
Existing gene-based dosing algorithms explained between approximately one-third and one-half of the variability in warfarin dose requirements in this racially and ethnically diverse cohort. Additional clinical and recently described genetic variants associated with warfarin dose did not enhance prediction in our patient population.

Download full-text


Available from: Malgorzata Jaremko, Mar 23, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I(2) = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.Clinical Pharmacology & Therapeutics (2012); advance online publication 7 November 2012. doi:10.1038/clpt.2012.184.
    Clinical Pharmacology &#38 Therapeutics 11/2012; DOI:10.1038/clpt.2012.184 · 7.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Time-dependent-dielectric-breakdown (TDDB) distributions obtained from oxides of the same physical geometry and stressed at the same electric field were found to shift to shorter times when the amount of energy available to flow through electric breakdowns was increased. This paper shows that TDDB distributions are nonunique and that for a breakdown model to accurately describe the reliability of an oxide during actual use conditions, the oxide thermal geometry must be taken into account. An accurate method of obtaining electric breakdown distributions is also presented which allows the use of smaller sample sizes to obtain time-dependent-electric-breakdown (TDEB) distributions which are similar to TDDB distributions
    Integrated Reliability Workshop Final Report, 1997 IEEE International; 11/1997
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A total of 371 patients under stable warfarin therapy were retrospectively selected to develop a pharmacogenetic algorithm to identify the individual maintenance dose. The variables that were entered into the algorithm were: VKORC1, CYP2C9 and CYP4F2 polymorphisms, body surface area and age. The percentage of cases whose predicted mean weekly warfarin dose was within 20% of the actual maintenance dose was 51.8% considering patients overall, and were 36.2, 66.2 and 55.4%, respectively, taking into account patients requiring low (≤25 mg/week), intermediate (25-45 mg/week) and high (≥45 mg/week) doses. The algorithm could correctly assign 73.8 and 63.2% of patients to the low- and high-dose regimens, respectively. We developed and validated a pharmacogenetic algorithm in a series of Italian patients, we then tested, in the same series of italian patients, the formulas of three published algorithms. These three algorithms were developed and validated by their authors in a series of patients different from our own. The performance of our algorithm in our patients series was slightly higher than that achieved when using the three other algorithms in our patients series. The high predictive accuracy of low and high warfarin requirements of our algorithm warrants its application in prospective studies for clinical validation.
    Pharmacogenomics 01/2010; 12(1):15-25. DOI:10.2217/pgs.10.162 · 3.43 Impact Factor